CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the ...

As shelf-stable microarray patch (MAP) platforms move through development and clinical work, a ‘packaging first’ mentality is needed for industry-wide adoption.

With the April 2005 release of its Little Dipper Microarray Processing System, Sunnyvale, Calif.-based SciGene has now completed its benchtop system for automated microarray processing from ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

Foot soldiers in the "Omics revolution" have an ally in the BioOdyssey Calligrapher MiniArrayer, a new entry into the benchtop microarray printing arena from Bio-Rad Laboratories. The $25,000 (US) ...

A study of US-based Indian and Pakistani population with cancer diagnosis reported in the SEER database from 1988 to 2002 Patients with CUP constitute approximately 5% of all malignancies and have no ...

Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

Randomised, double blind, placebo-controlled, multi-centre, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy No significant ...